Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Accounts Payables: 2019-2024

Historic Accounts Payables for Revolution Medicines (RVMD) over the last 6 years, with Dec 2024 value amounting to $54.4 million.

  • Revolution Medicines' Accounts Payables rose 206.06% to $74.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.8 million, marking a year-over-year increase of 206.06%. This contributed to the annual value of $54.4 million for FY2024, which is 11.91% down from last year.
  • Latest data reveals that Revolution Medicines reported Accounts Payables of $54.4 million as of FY2024, which was down 11.91% from $61.8 million recorded in FY2023.
  • Over the past 5 years, Revolution Medicines' Accounts Payables peaked at $61.8 million during FY2023, and registered a low of $12.6 million during FY2020.
  • For the 3-year period, Revolution Medicines' Accounts Payables averaged around $45.8 million, with its median value being $54.4 million (2024).
  • Its Accounts Payables has fluctuated over the past 5 years, first surged by 190.00% in 2023, then fell by 11.91% in 2024.
  • Yearly analysis of 5 years shows Revolution Medicines' Accounts Payables stood at $12.6 million in 2020, then climbed by 11.48% to $14.1 million in 2021, then soared by 51.57% to $21.3 million in 2022, then spiked by 190.00% to $61.8 million in 2023, then declined by 11.91% to $54.4 million in 2024.